Emergent BioSolutions Inc.
EBS evidence brief
What we can confirm
- BioSniper Score:
- 4.4 / 10
- Market Cap:
- $301.0M
- Lead Asset:
- anthrasil (Approved)
What it means
What to watch
Prepared research question
What matters most for EBS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · EBS
Emergent BioSolutions Inc. (EBS) is a public biotech company focused on medical countermeasures for public health threats, including anthrax, smallpox, mpox, and opioid overdose, with a portfolio of approved products and government contracts.
Key risk: Large net loss
BioSniper Score
Based on 5 of 6 signals
Market Cap
$301.0M
Cash Runway
—
Lead Asset
anthrasil (Approved)
Next Catalyst
Patent_Expiry · Oct 10, 2034Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 15 clinical trials · 1 catalyst for Emergent BioSolutions Inc..
Emergent BioSolutions Inc. (EBS) is a public biotech company focused on medical countermeasures for public health threats, including anthrax, smallpox, mpox, and opioid overdose, with a portfolio of approved products and government contracts.
- Cash & equivalents of $139.7M as of 2026-06-30 [sec]
- Total revenue of $234.3M and net income of -$180.2M for the period ending 2026-06-30 [sec]
- Shareholders' equity of $341.4M as of 2026-06-30 [sec]
- Awarded a standing offer by the Government of Canada to supply NARCAN Nasal Spray through September 2029 [news · published 2026-08-31]
- Secured a ~$54M contract to provide CNJ-016 (VIGIV) to the U.S. Department of Health and Human Services [news · published 2026-03-26]
What works
- Approved product Anthrasil for inhalational anthrax treatment, with a competitive landscape including several Phase 2/3 candidates [pipeline]
- Multiple government contracts and standing offers, including a ~$54M contract for CNJ-016 and a Canadian standing offer for NARCAN Nasal Spray [news · published 2026-03-26][news · published 2026-08-31]
- Positive Q1 2026 financial results with net income of $6.8 million and adjusted EBITDA of $35.6 million [news · published 2026-04-30]
What to weigh
- Net loss of -$180.2M for the period ending 2026-06-30, indicating significant unprofitability [sec]
- Reliance on government contracts and public health procurement, which may be subject to political and budgetary changes [news · published 2026-03-26][news · published 2026-08-31]
- Pipeline appears limited with no disclosed novel candidates beyond approved products and early-phase studies for AV7909 and COVID-HIGIV [catalyst][pipeline]
From the filings
Quoted directly from source documents.
Canadian standing offer for NARCAN Nasal Spray
“awarded a standing offer by the Government of Canada, through a competitive procurement process, to supply NARCAN® Nasal Spray”
News · August 31, 2026
Contract for CNJ-016 to U.S. government
“secured a contract award valued at approximately $54 million USD to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the”
News · March 26, 2026
Catalyst timeline
- 2034-10-10 · Patent_Expiry · BRINCIDOFOVIR — Patent expiry for NDA214461, which may affect exclusivity for that product.
Risks & what to watch (3)›
Key risks
- Large net loss — Net loss of -$180.2M as of 2026-06-30, indicating financial strain [sec]
- Government contract dependency — Revenue heavily reliant on government contracts, which may be non-recurring or subject to policy shifts [news · published 2026-03-26]
- Limited pipeline depth — No disclosed novel pipeline candidates beyond approved products and early-phase studies [catalyst][pipeline]
What to watch
- Ability to sustain profitability after Q1 2026 net income of $6.8M [news · published 2026-04-30]
- Execution of Canadian NARCAN standing offer through September 2029 [news · published 2026-08-31]
- Potential for additional government contracts or expanded approvals for ACAM2000 [news · published 2026-05-20]
- Patent expiry for BRINCIDOFOVIR on 2034-10-10 [catalyst]
Sources: Catalysts · Competitor trials · News · Pipeline · Generated October 11, 2026 · How we verify sources →
Run Emergent BioSolutions Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Emergent BioSolutions Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 2.27 · 0% dilution
Lead: Approved
1 candidate
1 upcoming, next in ~2918d
0 buys · 8 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of Apr 28, 2026- % of float
- 19.0%
- Days to cover
- 12.2
- Shares short
- 9,643,974
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
EBS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Emergent BioSolutions Inc.?
Emergent BioSolutions Inc. (EBS) is a public biotech company focused on medical countermeasures for public health threats, including anthrax, smallpox, mpox, and opioid overdose, with a portfolio of approved products and government contracts.
What is Emergent BioSolutions Inc.'s lead drug candidate?
Emergent BioSolutions Inc.'s most advanced tracked candidate is anthrasil (Approved) for Treatment of inhalational anthrax.
What is Emergent BioSolutions Inc.'s next catalyst?
Emergent BioSolutions Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA214461" — expected October 10, 2034.
Who is the CEO of Emergent BioSolutions Inc.?
Mr. Joseph C. Papa Jr., M.B.A., R.Ph. is the chief executive officer of Emergent BioSolutions Inc. (EBS).
Where is Emergent BioSolutions Inc. headquartered?
Emergent BioSolutions Inc. (EBS) is headquartered in Gaithersburg, MD, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.